Organ-protective and immunomodulatory effects of erythropoietin--an update on recent clinical trials (Q37946499)

25 August 2017

title

Organ-protective and immunomodulatory effects of erythropoietin--an update on recent clinical trials (English)

1 reference

25 August 2017

1 reference

Christoffer Sølling

1 reference

25 August 2017

publication date

9 November 2011

1 reference

Basic and Clinical Pharmacology and Toxicology

25 August 2017

published in

1 reference

25 August 2017

volume

110

1 reference

25 August 2017

1 reference

25 August 2017

page(s)

113-121

1 reference

Statins: panacea for sepsis?

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Acute hyperinsulinemia restrains endotoxin-induced systemic inflammatory response: an experimental study in a porcine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Endothelial Damage and Regeneration: The Role of the Renin-Angiotensin-Aldosterone System

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Erythropoietin after a century of research: younger than ever

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Molecular biology of erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Structures and functional roles of the sugar chains of human erythropoietins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Structure, production and function of erythropoietin: implications for therapeutical use in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

New avenues of exploration for erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

The erythropoietin receptor in normal and cancer tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

The non-haematopoietic biological effects of erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Postnatal erythropoietin treatment mitigates neural cell loss after systemic prenatal hypoxic-ischemic injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Erythropoietin does not attenuate renal dysfunction or inflammation in a porcine model of endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Low-dose erythropoietin aggravates endotoxin-induced organ damage in conscious rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Efficacy and safety of epoetin alfa in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Recombinant human erythropoietin in the treatment of acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Circulating damage marker profiles support a neuroprotective effect of erythropoietin in ischemic stroke patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. Clinical article

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

The erythropoietin neuroprotective effect: assessment in CABG surgery (TENPEAKS): a randomized, double-blind, placebo controlled, proof-of-concept clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

A single dose of erythropoietin in ST-elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Evaluation of the effect of one large dose of erythropoietin against cardiac and cerebral ischemic injury occurring during cardiac surgery with cardiopulmonary bypass: a randomized double-blind placebo-controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Two large preoperative doses of erythropoietin do not reduce the systemic inflammatory response to cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Erythropoietin augments the cytokine response to acute endotoxin-induced inflammation in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Coagulation Studies and Fistula Blood Flow During Erythropoietin Therapy in Haemodialysis Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Anemia management in oncology and hematology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

2009: a requiem for rHuEPOs--but should we nail down the coffin in 2010?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Erythropoietin during porcine aortic balloon occlusion-induced ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Derivatives of erythropoietin that are tissue protective but not erythropoietic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Endogenous erythropoietin and a single bolus of 40,000 IU of epoetin alpha do not protect the heart from ischaemia-reperfusion injury during extracorporeal circulation for cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI-1 study -.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

Erythropoietin Prevention Trial of Coronary Restenosis and Cardiac Remodeling After ST-Elevated Acute Myocardial Infarction (EPOC-AMI) - A Pilot, Randomized, Placebo-Controlled Study -

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

High-dose erythropoietin in patients with acute myocardial infarction: A pilot, randomised, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2011.00820.X

10.1111/J.1742-7843.2011.00820.X

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference